According to the 2016 definitions of the WHO and the European Organization for Research and Treatment of Cancer (EORTC), it is incorporated in the primary cutaneous CD30 lymphoproliferative disorders [128,129]. Here, TNFRSF8 is linked to lymphoproliferative syndrome.